MCID: TXC002
MIFTS: 57

Toxic Encephalopathy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 54 15 17
Neurotoxicity Syndromes 77 54 45
Neurotoxicity 12 55 15
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 45 D020258
NCIt 51 C27961
SNOMED-CT 69 19466003
ICD10 34 G92
UMLS 74 C0235032

Summaries for Toxic Encephalopathy

NINDS : 55 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to alzheimer disease and ischemia. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian entrainment. The drugs Oxaliplatin and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and b cells, and related phenotypes are Decreased caspase 3/7 activity and behavior/neurological

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 77 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 31.3 ACHE APP BDNF CASP3 CYCS GRIN2A
2 ischemia 30.6 APP CASP3 CYCS HMOX1
3 status epilepticus 30.4 BDNF CASP3 GRIN2B
4 pheochromocytoma 30.3 CASP3 MAOB NGF TH
5 hearing loss, noise-induced 30.2 GSTM1 TH
6 peripheral nervous system disease 30.2 ACHE NGF PNPLA6
7 major depressive disorder 30.0 ABCB1 BDNF GRIN2B SLC6A3
8 frontotemporal dementia 30.0 ACHE APP PRNP SNCA
9 akinetic mutism 29.9 PRNP SLC6A3
10 fetal alcohol spectrum disorder 29.9 BDNF GRIN2A GRIN2B
11 huntington disease 29.8 BDNF CASP3 CYCS GRIN2A GRIN2B PRNP
12 movement disease 29.8 SLC6A3 SNCA TH
13 mood disorder 29.6 BDNF MAOB TH
14 alcohol dependence 29.6 BDNF GRIN2A GRIN2B MAOB SLC6A3
15 disease of mental health 29.6 APP BDNF GRIN2A GRIN2B SLC6A3 SNCA
16 amyotrophic lateral sclerosis 1 29.5 APP BDNF CASP3 CYCS MAOB NGF
17 aphasia 29.5 APP BDNF GRIN2A PRNP SNCA
18 dementia 29.4 ACHE APP BDNF ITIH4 PRNP SLC6A3
19 parkinson disease, late-onset 29.2 ACHE APP BDNF CASP3 CYCS HMOX1
20 schizophrenia 29.2 BDNF GRIN2A GRIN2B MAOB SLC1A2 SLC6A3
21 central nervous system disease 28.9 APP BDNF CASP3 HMOX1 MAOB NGF
22 nervous system disease 28.6 ACHE APP BDNF CASP3 GRIN2B MAOB
23 phenylketonuria 11.3
24 hepatic encephalopathy 11.3
25 fetal methylmercury syndrome 11.3
26 hypermanganesemia with dystonia 11.1
27 alzheimer disease 2 11.0
28 alzheimer disease mitochondrial 11.0
29 alzheimer disease 4 11.0
30 alzheimer disease 3 11.0
31 alzheimer disease 9 11.0
32 alzheimer disease 18 11.0
33 alzheimer disease 19 11.0
34 kernicterus 11.0
35 hyperbetaalaninemia 11.0
36 chronic bilirubin encephalopathy 11.0
37 encephalopathy 10.8
38 neuroblastoma 10.5
39 neonatal hypoxic and ischemic brain injury 10.4 BDNF TH
40 bile acid synthesis defect, congenital, 1 10.4 GRIN2A GRIN2B
41 tendinosis 10.4 ACHE BDNF TH
42 substance dependence 10.3 BDNF GSTM1 SLC6A3
43 epilepsy, focal, with speech disorder and with or without mental retardation 10.3 GRIN2A GRIN2B
44 alpha thalassemia-intellectual disability syndrome type 1 10.3 BDNF GRIN2A TH
45 valproate embryopathy 10.3 BDNF GRIN2A GRIN2B
46 perry syndrome 10.3 SLC6A3 SNCA TH
47 multiple system atrophy 1 10.3 SLC6A3 SNCA TH
48 rem sleep behavior disorder 10.3 ACHE SLC6A3 SNCA
49 hypoganglionosis 10.3 ACHE TH
50 neuropathy 10.3

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

GenomeRNAi Phenotypes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.92 APP CASP3 GRIN2A GRIN2B

MGI Mouse Phenotypes related to Toxic Encephalopathy:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 ABCB1 ABCG2 ACHE APP BDNF CASP3
2 cellular MP:0005384 10.36 ABCG2 APP BDNF CASP3 CYCS HMOX1
3 homeostasis/metabolism MP:0005376 10.36 ABCB1 ABCG2 ACHE APP BDNF CASP3
4 growth/size/body region MP:0005378 10.35 ABCB1 ACHE APP BDNF CASP3 CYCS
5 mortality/aging MP:0010768 10.28 ABCB1 ACHE APP BDNF CASP3 CYCS
6 nervous system MP:0003631 10.25 ABCB1 ABCG2 ACHE APP BDNF CASP3
7 cardiovascular system MP:0005385 10.18 ABCB1 APP CASP3 CYCS HMOX1 NGF
8 integument MP:0010771 10.17 ABCG2 APP BDNF CASP3 GRIN2A NGF
9 endocrine/exocrine gland MP:0005379 10.15 ABCB1 BDNF CASP3 CYCS HMOX1 PRNP
10 no phenotypic analysis MP:0003012 9.96 ABCB1 ACHE APP BDNF CASP3 GRIN2B
11 muscle MP:0005369 9.91 ACHE APP CASP3 HMOX1 NGF PRNP
12 normal MP:0002873 9.85 ABCG2 APP BDNF ITIH4 NGF PRNP
13 reproductive system MP:0005389 9.61 ABCB1 ACHE APP BDNF CASP3 HMOX1
14 taste/olfaction MP:0005394 8.92 BDNF CASP3 SLC6A3 SNCA

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 558)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 6857599 5310940 9887054 43805
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
4
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
5
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
6
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
9
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
10
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
11
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
12
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
13
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 113775-47-6 68602 5311068
14
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
15
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
16
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
17
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
18
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492 6473866
19
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
20
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
21
Lacosamide Approved Phase 4 175481-36-4, 860352-01-8 219078
22
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
23
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
24
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
25
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
26
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
27
Desflurane Approved Phase 4 57041-67-5 42113
28
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
29
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
30
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
31
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
32
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
33
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
34
Mycophenolic acid Approved Phase 4,Phase 2,Not Applicable 24280-93-1 446541
35
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
36
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
37
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
38
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
39
Levetiracetam Approved, Investigational Phase 4,Phase 2 102767-28-2 441341
40
Cobicistat Approved Phase 4,Not Applicable 1004316-88-4
41
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
42
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
43
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
44
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
45
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
46
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
47
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
48
Dolutegravir Approved Phase 4 1051375-16-6 54726191
49
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
50
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039

Interventional clinical trials:

(show top 50) (show all 505)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
3 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
4 Colistin Pharmacokinetics in Continuous Renal Replacement Therapy Unknown status NCT02081560 Phase 4 Colistin
5 Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children Unknown status NCT03022240 Phase 4 Propofol;Sevoflurane;Ametop;Ondansetron
6 Lipids and Neurological Complications in Liver Transplantation Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
7 Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Unknown status NCT02328183 Phase 4 Polymyxin B
8 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
9 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Completed NCT02051062 Phase 4
10 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
11 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
12 Thermal QST for Interscale Block Evaluation Completed NCT02271867 Phase 4
13 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
14 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
15 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
16 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
17 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
18 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
19 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
20 Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
21 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
22 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
23 Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Recruiting NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
24 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4 Colistin;Tobramycin
25 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
26 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Active, not recruiting NCT01935128 Phase 4 Arm 1 Everolimus/Reduced dose tacrolimus
27 Envarsus Neurotoxicity Burden in Liver Transplant Patients Not yet recruiting NCT03823768 Phase 4 Envarsus;Tacrolimus Immediate release
28 A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) Not yet recruiting NCT03685500 Phase 4 Symtuza® (TAF/FTC/DRV/c);ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
29 Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia Not yet recruiting NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
30 L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
31 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
32 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
33 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
34 Pain Management After Total Shoulder Arthroplasty Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
35 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
36 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
37 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
38 Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
39 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
40 Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
41 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Unknown status NCT02024191 Phase 3
42 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
43 Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery Unknown status NCT03067896 Phase 3 Bupivacaine;Dexmedetomidine;Magnesium Sulfate
44 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
45 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
46 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
47 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
48 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
49 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 Ganglioside-monosialic acid;placebo
50 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

42
Brain, T Cells, B Cells, Skin, Colon, Bone, Prostate

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 139)
# Title Authors Year
1
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. ( 29719722 )
2018
2
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. ( 29973469 )
2018
3
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. ( 28153514 )
2017
4
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. ( 28173825 )
2017
5
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
6
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. ( 28748330 )
2017
7
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. ( 29121830 )
2017
8
Routine fruit washing to prevent acute toxic encephalopathy. ( 28807178 )
2017
9
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
10
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
11
Neem oil poisoning - Case report of an adult with toxic encephalopathy. ( 27728581 )
2016
12
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
13
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
14
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2015
15
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
16
1,2-Dichloroethane-induced toxic encephalopathy: A case series with morphological investigations. ( 25743226 )
2015
17
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
18
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
19
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2014
20
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
21
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
22
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
23
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
24
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
25
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
26
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
27
Toxic encephalopathy. ( 22362126 )
2012
28
Toxic encephalopathy. ( 23251840 )
2012
29
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
30
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
31
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
32
Toxic encephalopathy. ( 21590623 )
2011
33
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
34
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
35
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
36
[Star fruit (Averrhoa carambola) toxic encephalopathy]. ( 18755486 )
2009
37
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
38
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
39
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
40
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
41
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
42
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
43
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
44
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
45
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
46
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
47
Taurine induced toxic encephalopathy? ( 16844286 )
2006
48
Methadone intoxication in a child: toxic encephalopathy? ( 16970857 )
2006
49
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006
50
Toxic encephalopathy and noise-induced hearing loss. ( 17851218 )
2006

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 APP BDNF CASP3 CYCS GRIN2A GRIN2B
2
Show member pathways
12.87 ACHE GRIN2A GRIN2B MAOB SLC1A2 SLC6A3
3 12.04 BDNF CASP3 NGF TH
4 11.95 BDNF CASP3 GRIN2B NGF
5
Show member pathways
11.82 CASP3 CYCS GRIN2A GRIN2B SLC1A2
6 11.76 APP GRIN2A GRIN2B NGF PRNP SLC1A2
7 11.6 CASP3 CYCS GSTM1
8 11.6 ABCG2 BDNF NGF TH
9 11.58 CASP3 CYCS SLC6A3 SNCA TH
10 11.54 ABCB1 ABCG2 HMOX1
11
Show member pathways
11.5 BDNF GRIN2A GRIN2B MAOB SLC6A3 TH
12 11.44 APP CASP3 PRNP
13
Show member pathways
11.37 APP BDNF CASP3 CYCS NGF
14
Show member pathways
11.32 ACHE SLC6A3 TH
15 11.13 MAOB SLC6A3 SNCA TH
16 10.97 ABCB1 CASP3 CYCS
17 10.74 MAOB TH
18 10.73 BDNF CASP3
19 10.69 ABCB1 ABCG2
20 10.65 ACHE TH

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.8 ACHE APP GRIN2A GRIN2B SNCA
2 neuron projection GO:0043005 9.65 APP GRIN2A GRIN2B SLC6A3 TH
3 membrane raft GO:0045121 9.62 APP CASP3 PRNP SLC6A3
4 cell surface GO:0009986 9.56 ABCB1 ACHE APP GRIN2A GRIN2B PRNP
5 synaptic vesicle GO:0008021 9.55 BDNF GRIN2A NGF SNCA TH
6 NMDA selective glutamate receptor complex GO:0017146 9.37 GRIN2A GRIN2B
7 axon GO:0030424 9.17 APP BDNF NGF SLC1A2 SLC6A3 SNCA

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.96 GRIN2A GRIN2B SLC1A2 SNCA
2 positive regulation of apoptotic process GO:0043065 9.96 CASP3 GRIN2A HMOX1 NGF SNCA
3 response to lipopolysaccharide GO:0032496 9.88 CASP3 MAOB SNCA TH
4 locomotory behavior GO:0007626 9.85 APP SLC6A3 TH
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 CASP3 NGF SNCA
6 negative regulation of neuron apoptotic process GO:0043524 9.85 BDNF HMOX1 NGF SNCA
7 excitatory postsynaptic potential GO:0060079 9.81 GRIN2A GRIN2B SNCA
8 modulation of chemical synaptic transmission GO:0050804 9.78 BDNF GRIN2A NGF
9 learning GO:0007612 9.77 APP GRIN2A TH
10 long-term synaptic potentiation GO:0060291 9.74 GRIN2A GRIN2B SNCA
11 memory GO:0007613 9.73 BDNF GRIN2A NGF TH
12 positive regulation of neuron death GO:1901216 9.71 GRIN2B PRNP SNCA
13 response to wounding GO:0009611 9.71 ACHE CASP3 GRIN2A SLC1A2
14 cellular response to amyloid-beta GO:1904646 9.69 APP GRIN2A PRNP
15 dopamine metabolic process GO:0042417 9.68 GRIN2A SNCA
16 glutamate receptor signaling pathway GO:0007215 9.68 GRIN2A GRIN2B
17 cellular copper ion homeostasis GO:0006878 9.68 APP PRNP
18 nerve development GO:0021675 9.68 BDNF NGF
19 nerve growth factor signaling pathway GO:0038180 9.67 BDNF NGF
20 cellular response to copper ion GO:0071280 9.67 APP PRNP SNCA
21 negative regulation of activated T cell proliferation GO:0046007 9.66 CASP3 PRNP
22 negative regulation of long-term synaptic potentiation GO:1900272 9.65 APP PRNP
23 neuron projection maintenance GO:1990535 9.65 APP PRNP
24 neurotransmitter catabolic process GO:0042135 9.65 ACHE MAOB
25 ionotropic glutamate receptor signaling pathway GO:0035235 9.65 APP GRIN2A GRIN2B
26 cellular response to manganese ion GO:0071287 9.64 APP TH
27 dopamine catabolic process GO:0042420 9.63 MAOB SLC6A3
28 excitatory chemical synaptic transmission GO:0098976 9.63 GRIN2A GRIN2B
29 neurotrophin TRK receptor signaling pathway GO:0048011 9.63 BDNF CASP3 NGF
30 mating behavior GO:0007617 9.62 APP TH
31 positive regulation of collateral sprouting GO:0048672 9.62 BDNF NGF
32 xenobiotic transport GO:0042908 9.61 ABCB1 ABCG2
33 calcium ion transmembrane import into cytosol GO:0097553 9.59 GRIN2A GRIN2B
34 modulation of age-related behavioral decline GO:0090647 9.58 APP PRNP
35 response to nicotine GO:0035094 9.56 CASP3 HMOX1 SLC6A3 TH
36 response to ethanol GO:0045471 9.55 GRIN2A GRIN2B MAOB SLC6A3 TH
37 neurotransmitter biosynthetic process GO:0042136 9.54 ACHE SLC6A3 TH
38 negative regulation of dendritic spine maintenance GO:1902951 9.52 GRIN2B PRNP
39 dopamine biosynthetic process GO:0042416 9.5 SLC6A3 SNCA TH
40 learning or memory GO:0007611 9.35 APP CASP3 GRIN2A GRIN2B PRNP
41 response to drug GO:0042493 9.28 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC1A2

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.61 CASP3 PRNP SLC6A3
2 ionotropic glutamate receptor activity GO:0004970 9.4 GRIN2A GRIN2B
3 dopamine binding GO:0035240 9.37 SLC6A3 TH
4 enzyme binding GO:0019899 9.35 APP GSTM1 HMOX1 SNCA TH
5 NMDA glutamate receptor activity GO:0004972 9.32 GRIN2A GRIN2B
6 cuprous ion binding GO:1903136 9.26 PRNP SNCA
7 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.16 ABCB1 ABCG2
8 glutamate-gated calcium ion channel activity GO:0022849 8.62 GRIN2A GRIN2B

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....